Case studies of the hepatitis B patient: A panel discussion

Seminars in Liver Disease

Volumn 20, Issue 1 SUPPL., 2000, Pages 29-35

  Vierling, John M ^a   Teperman, Lewis W ^b   Lake, John R ^c   Perrillo, Robert P ^d   Peters, Marion ^e   Fried, Michael ^f   Schiff, Eugene R ^g,h  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d OCHSNER CLINIC FOUNDATION   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f EMORY UNIVERSITY   (United States)

^g UNIVERSITY OF MIAMI   (United States)

^h Center for the Study of Liver Diseases   (United States)

Author keywords

Case studies; Hepatitis B; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; NUCLEOSIDE ANALOG;

CASE REPORT; CONFERENCE PAPER; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MALE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT PLANNING; VIRUS MUTANT;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS ANTIGENS; HEPATITIS B; HUMANS; IMMUNIZATION, PASSIVE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; QUALITY OF LIFE; RECURRENCE; RISK FACTORS;

EID: 0033917297     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Perrillo R, Rakela J, Martin P, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation (OLT) [abstract]. Hepatology 1997;26:260a
2. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in live transplant recipients using a fixed dose schedule of hepatitis B immunoglobulin. Hepatology 1996;24:1327-1333
3. Villamil FG, Vierling JM. Recurrence of viral hepatitis after liver transplantation: Insights into management. Liver Transplant Surg 1995;1(5 Suppl 1):89-99
4. Sawyer RG, McGory RW, Galley MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998;227:841-850
5. Dienstag J.L., Perrillo RP, Schiff EP, Bartholomew M. Vicary C. Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661
6. Bartholomew MM, Jansen RW, Jeffers LH, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1996;348:1212-1215
7. Perrillo R, Rakela J, Martin P, et al. Long-term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation [abstract]. Hepatology 1997;26:177a
8. Decks SG, Collier A, Lalezari J, et al. The safely and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: A randomized. double-blind, placebo-controlled trial. J Infect Dis 1997;176:1517-1523
9. Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activity, safely, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997;176:406-413
10. Mulato AS, Lamy PD, Miller MD, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type I variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 1998;42: 1620-1628
11. Nicoll A, Locarnini S. Review: Present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 1997;12:843-854
12. Shields PL, Ling R, Harrison T, et al. Management and outcome of lamivudine (LAM) resistant hepatitis B virus (HBV) infection after liver transplantation [abstract]. Hepatology 1997;26:260a
13. Dumortier J, Durupt S, Chevallier M, Trepo C, Zoulim F. Favorable course of hepatitis B virus reactivation with hepatocellular insufficiency by a treatment combining corticoids, forcarnel and ganciclovir. Gastroenterol Clin Biol 1997;21:982-986 [French]
14. McMaster P, Gunson B, Min X, Afonso R, Bastos J. Liver transplantation: Changing goals in immunosuppression. Transplant Proc 1998;30:1819-1821
15. Gish RG, Keefe EB, Lim J, et al. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. Hepatology 1995;22:257-262
16. Bronsther O, Ersoz S, Tugcu M, et al. Liver transplantation for HBV-related disease under immunosuppression with tacrolimus: An experience with 78 consecutive cases. J Okla State Med Assoc 1995;88:103-108
17. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transplant Surg 1997;3:105-111
18. Turner DP, Zuckerman M, Alexander GJ, Waite J. Wreghitt T. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997;63: 775-777
19. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61:1358-1364
20. Davern TJ, Lake JR. Recurrent disease after liver transplantation. Semin Gastrointest Dis 1998;9:86-109
21. Bismuth H, Samuel D, Castaing D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995;222:109-119
22. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847
23. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998;28:585-589
24. Uemoto S, Sugiyama K, Inomata Y, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998;65:494-499
25. Palma LD. Diagnostic imaging and interventional therapy of hepatocellular carcinoma. Br J Radiol 1998;71(848):808-818
26. Kanematsu M, Hoshi H, Murakami T, et al. Detection of hepatocellular carcinoma in patients with cirrhosis: MR imaging versus angiographically assisted helical CT. AJR Am J Roentgenol 1997;169:1507-1515
27. Adam R, Castaing D, Azoulay D, Majno P, Samuel D, Bismuth H. Indications and results of liver transplantation in the treatment of hepatocellular carcinoma in cirrhosis. Ann Chir 1998;52:547-557
28. Trinchet JC, Ganne-Carrie N, Beaugrand M. Intra-arterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology 1998;45(Suppl 3):1242-1247
29. Pelletier G, Ducreux M, Gay F. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J Hepatol 1998;29: 129-134
30. Francica G, Marone G, D'Angelo V, et al. Relapsing neoplastic seeding alter percutaneous ethanol injectin for hepatocellular carcinoma. Clinical and ultrasonographic findings in a cirrhotic patient. Eur J Ultrasound 1997;6:185-189
31. Ishii H, Okada S, Okusaka T, et al. Needle tract implantation of hepatocellular carcinoma alter percutaneous injection. Cancer 1998;82:1638-1642
32. Allgaier HP, Deibert P, Zuber I, Blum HE. Percutaneous treatment of liver tumors using interstitial radiofrequency thermoablation. A new therapeutic strategy. Dtsch Med Wochenschr 1998;123:907-911
33. Nagata Y, Hiraoka M, Mishimura Y, et al. Clinical results of radiofrequency hyperthermia for malignant liver tumors. Int J Radiat Oncol Biol Phys 1997;38:359-365
34. Watanabe Y, Sato M, Abe Y, et al. Laparoscopic microwave coagulonecrotic therapy for hepatocellular carcinoma: A feasible study of an alternative option for poor-risk patients. J Laparoendosc Surg 1995;5:169-175
35. Ghany M, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in recipients who were reinfected despite prophylaxis. Hepatology 1998;27:213-222
36. Turcotte JG, Magee JC, Bromberg JS, et al. Update of the Adult and Pediatric Liver Transplant Program at the University of Michigan. Clin Transplant 1996;10:203-216